Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges

References

• Global HIV & AIDS statistics — 2018 fact sheet: UNAIDS; 2018. [cited 2019 May 20]. Available from: https://www.unaids.org/en/resources/fact-sheet.
   Google Scholar
• Medlock J, Pandey A, Parpia AS, et al. Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci U S A. 2017;114(15):4017–4022.
   PubMed Web of Science ®Google Scholar
• Harmon TM, Fisher KA, McGlynn MG, et al. Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in low- and middle-income countries. PloS One. 2016;11(1):e0146387.
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–665.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006;194(12):1661–1671.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–515.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Sheets RL, Zhou T, Knezevic I. Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines - A review from a regulatory perspective. Biologicals. 2016;44(2):90–110.
   PubMed Web of Science ®Google Scholar
• Li SX, Sen S, Schneider JM, et al. Gut microbiota from high-risk men who have sex with men drive immune activation in gnotobiotic mice and in vitro HIV infection. PLoS Pathog. 2019;15(4):e1007611.
   PubMed Web of Science ®Google Scholar
• Baden LR, Karita E, Mutua G, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann Intern Med. 2016;164(5):313–322.
   PubMed Web of Science ®Google Scholar
• Kratochvil S, McKay PF, Kopycinski JT, et al. A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens. Front Immunol. 2017;8:595.
   PubMed Web of Science ®Google Scholar
• Choi E, Michalski CJ, Choo SH, et al. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology. 2016;13(1):82.
   PubMedGoogle Scholar
• Priddy FH, Lewis DJM, Gelderblom HC, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019;6(4):e230–e9.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Excler JL, et al. Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J Infect Dis. 2017;215(8):1255–1263.
   PubMed Web of Science ®Google Scholar
• Easterhoff D, Moody MA, Fera D, et al. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017;13(2):e1006182–e.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Nitayaphan S, Chariyalertsak S, et al. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected thai volunteers, a randomised controlled trial. Lancet HIV. 2020. Forthcoming.
   PubMedGoogle Scholar
• Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013;208(3):418–422.
   PubMed Web of Science ®Google Scholar
• Regules JA, Cicatelli SB, Bennett JW, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214(5):762–771.
   PubMed Web of Science ®Google Scholar
• Bekker LG, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018;5(7):e366–e78.
   PubMed Web of Science ®Google Scholar
• Developing a vaccine against HIV infection: AVERT; 2019 [cited 2019 Jun 28]. Available from: https://www.avert.org/professionals/hiv-science/developing-vaccine
   Google Scholar
• Fischer W, Liao HX, Haynes BF, et al. Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol. 2008;4(1):e15. author reply e25. .
   PubMed Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, et al. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia ankara vector. J Infect Dis. 2018;218(4):633–644.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392(10143):232–243.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang S, Lu S. DNA Immunization for HIV vaccine development. Vaccines (Basel). 2014;2(1):138–159.
   PubMedGoogle Scholar
• IAVI report: IAVI; 2019 [cited 2019 Jun 21]. Available from: https://www.iavireport.org/Back-Issues/Documents/IR_Vol23No1_2019.pdf.
   Google Scholar
• HIV research in the era of PREP: the implications of TDF/FTC for biomedical prevention trials: treatment action group; 2017 [cited 2019 Jun 28]. Available from: http://www.treatmentactiongroup.org/sites/default/files/PrEP%20Prevention%20Trials%20FINAL.pdf
   Google Scholar
• Pyra MN, Haberer JE, Hasen N, et al. Global implementation of PrEP for HIV prevention: setting expectations for impact. J Int AIDS Soc. 2019;22(8):e25370.
   PubMed Web of Science ®Google Scholar
• Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983.
   PubMed Web of Science ®Google Scholar
• Flash CA, Dale SK, Krakower DS. Pre-exposure prophylaxis for HIV prevention in women: current perspectives. Int J Womens Health. 2017;9:391–401.
   PubMed Web of Science ®Google Scholar
• Janes H, Donnell D, Gilbert PB, et al. Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. Lancet HIV. 2019;6(7):e475–e82.
   PubMed Web of Science ®Google Scholar
• Voronin Y, Zinszner H, Karg C, et al. HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians. Vaccine. 2015;33(10):1243–1249.
   PubMed Web of Science ®Google Scholar
• Lavreys L, Vingerhoets J, Colfer A, et al. vaccine induced seropositivity in participants of the APPROACH study. The HIV research for prevention HIVR4P 2018 conference; Madrid, Spain; 2018.
   Google Scholar
• Penezina O, Krueger NX, Rodriguez-Chavez IR, et al. Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants. Clin Vaccin Immunol. 2014;21(3):391–398.
   PubMedGoogle Scholar
• Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PloS One. 2012;7(8):e41936.
   PubMed Web of Science ®Google Scholar